TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04270448

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor Sequence Task
Description: Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Sequence Task
Description: Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Sequence Task
Description: Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear.
Study: NCT00496964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A + exercise
Description: Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
Study: NCT01287910

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Description: Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
Study: NCT02301910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase
Description: 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
Study: NCT00509262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Sitagliptin
Description: Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Glipizide
Description: Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
Study: NCT02454361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: KBP-7072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: KBP-7072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: KBP-7072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: KBP-7072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: KBP-7072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: KBP-7072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00402233

Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexole
Study: NCT06057311

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The Control Group (CG) did not receive any training. The assessments were applied twice to CG at baseline and after 6 weeks. The treatments and assessments were performed by the same physiotherapist in the same environment.
Study: NCT04114305

Intervention type: BEHAVIORAL
Intervention: ECD Intervention
Description: Modeled on the Early Learning Resource Unit's Family \& Community Motivator home visiting program and Philani Mentor Mothers home visiting program in South Africa. Program provided stimulation in 5 domains: cognitive, receptive and expressive language, gross and fine motor skills, also covered topics in maternal and child health, nutrition and social services.~Comprised primarily of home visits beginning during pregnancy and continuing until the child was 18 months. ECD MM taught the parent/caregiver about ages and stages of growth, helped facilitate responsive parenting and early learning opportunities for their children, demonstrated use of toys and books to stimulate the child, provided families with picture books, and taught caregivers to create toys and books for their child. Community parenting information play groups and educational talks on ECD at the clinic supplemented home visits.
Study: NCT04723095

Intervention type: OTHER
Intervention: Follow-Up
Description: Receive follow up
Study: NCT02301910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: 50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~* 55 to \<60 30 mg 6 ml~* 60 to \<70 35 mg 7 ml~* 70 to \<80 40 mg 8 ml
Study: NCT04723095

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical records
Study: NCT02145130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denovoDerm
Description: Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denovoSkin
Description: Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
Study: NCT01757600

Intervention type: OTHER
Intervention: Microperimetry
Study: NCT03638739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twice-weekly exercise
Description: An individualized exercise plan, incorporating aerobic and resistance exercises, following the Physical Activity Guideline recommendations will be provided for each participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twice-weekly exercise
Description: An individualized exercise plan, incorporating aerobic and resistance exercises, following the Physical Activity Guideline recommendations will be provided for each participant.
Study: NCT02426762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:~* 4-5 trocar-produced incisions (5/10mm, minor incision)~* 1 sample-retrieval incision (4-5cm, small incision)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin sealant
Description: After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
Study: NCT02040142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Study: NCT04287322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile-kinesthetic stimulation
Description: Tactile-kinesthetic stimulation involved three sessions per day; morning, afternoon, and evening for 10 days starting day 3 of life (initial contact). The stimulation included three phases; Phase 1: With neonates in prone position, moderate pressure was used to provide 12 strokes with palms of the hands, each stroke lasting 5 seconds. The strokes were provided in each area as follows: head, neck, shoulders and back.~Phase 2: In supine position, twelve moderate pressure strokes with palms of the hands, 5 seconds each, were provided in each area as follows:forehead,cheeks,chest, abdomen, upper limbs (each separately), lower limbs, palms and soles.~Phase 3: Kinesthetic stimulation was done for 5 minutes. The intervention comprised five passive flexion and extension movements of each large joint.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recorded maternal voice
Description: Following informed written consent from mothers,maternal voice was recorded (5 minutes talking to her baby and 10 minutes singing) using Philips Electronics, SA2RGA04KS, Netherlands. Recorded voice was played back inside the incubator or cot via micro audio system, which has been validated for safety and feasibility in previous studies (Doheny et al., 2012. Preterm neonate lay in supine/lateral position and recorded maternal voice was played for 15 minutes three times a day (morning, afternoon, evening) starting on day 3 of life up to day 12 of life (10 days).
Study: NCT01882257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP/AVAPS (Phillips Respironics)
Description: BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
Study: NCT05037604

Intervention type: OTHER
Intervention: Physical Examination
Description: Physical Examination made by a dermatologist

Intervention type: OTHER
Intervention: Physical Examination
Description: Physical Examination made by a dermatologist
Study: NCT04065308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Combinations
Description: Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response \<CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~1. dexamethasone :40mg/day D1-4, intravenous~2. cyclophosphamide: 400mg/m2 D1-4, intravenous~3. etoposide: 40mg/m2 D1-4, intravenous~4. cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle
Study: NCT01408641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules without topiramate
Study: NCT02619851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Description: Dressing for Second Deep degree Burn injury

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Typical therapy conducted for burn injury patients
Study: NCT03303001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subacromial high volume infiltration
Description: This group will receive a high volume dose of a mix of methylprednisolone (40 mg in 2 mL) plus ropivacaine at 7.5% plus simple lidocaine plus saline solution for a total of 50 mL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subacromial conventional infiltration
Description: This group will receive a mix of solution of 2 mL of 40 mg of methylprednisolone plus 5 ml of ropivacaine at 7.5% plus 3 mL of lidocaine simple for a total of 10 ml
Study: NCT00963950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal cholecystectomy
Description: Transvaginal approach to gallbladder removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy
Study: NCT01893749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH-IT
Description: It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
Study: NCT02740309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Brief Behavior Therapy (IBBT) Intervention
Description: The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Facilitated community referral for mental health treatment
Study: NCT04320836

Intervention type: PROCEDURE
Intervention: Cervical epidural steroid injection
Description: Interlaminar cervical epidural steroid injection with steroid and normal saline at C6-7 and C7-T1 (standard of care).
Study: NCT02867306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)
Description: Oral
Study: NCT02867007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2455
Description: oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: i.v. administration
Study: NCT02804360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dexamethasone injection
Description: intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
Study: NCT02034045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Paramedicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT01921998

Intervention type: PROCEDURE
Intervention: Biomarker and health economics
Description: Biomarkers CK18 and FLT3 Ligand will be collected
Study: NCT02663986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training (OST) Intervention
Study: NCT01605903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
Study: NCT03521947

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood picture
Description: Iaboratory investigation
Study: NCT03283085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Ontamalimab
Description: Ontamalimab SC solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Ontamalimab
Description: Ontamalimab SC solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Ontamalimab
Description: Ontamalimab SC solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Ontamalimab
Description: Ontamalimab SC solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg Ontamalimab
Description: Ontamalimab SC solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg Ontamalimab
Description: Ontamalimab SC solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg Ontamalimab
Description: Ontamalimab SC solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg Ontamalimab
Description: Ontamalimab SC solution for injection
Study: NCT00212407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Study: NCT02038348

Intervention type: DEVICE
Group type: OTHER
Intervention: PET with 18F-FDOPA
Study: NCT01832740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: oscillating direct current brain stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: no stimulation
Study: NCT01731002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.01%
Description: Administered to study eye, once daily (QD) in the evening (PM) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: Administered to study eye, QD in the PM for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005%
Description: Administered to study eye, QD in the PM for 28 days
Study: NCT03461055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender
Description: Lavender aromatherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water
Study: NCT03809897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
Study: NCT00686543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole will be used for prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole will be used for prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole will be used for prophylaxis
Study: NCT02631720

Intervention type: PROCEDURE
Intervention: Blood Draw

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Study: NCT01027117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revatio
Description: Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revatio
Description: Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revatio
Description: Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
Study: NCT02221609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment based on Movement System Impairment model
Description: The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General exercise
Description: The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
Study: NCT01393093

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization